ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
"More" Artificial mRNAs: Beyond the Art of Nature.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Messenger RNA (mRNA) has emerged as a versatile platform for gene expression and therapeutic innovation. Early engineering efforts focused on optimizing canonical mRNA components-the 5' cap, untranslated regions, coding sequence, and poly(A) tail-to enhance stability, translational efficiency, and safety. These refinements culminated in the success of mRNA vaccines and consequently enabled diverse biomedical applications ranging from gene and cell therapy to genome editing. More recently, research has expanded beyond the structural constraints of natural mRNAs, giving rise to non-canonical architectures, such as circular, branched, self-amplifying, and lantern-shaped RNAs. These designs confer novel properties, including resistance to degradation, autonomous replication, and programmable control of translation. Progress in chemical modification, ribozyme engineering, and RNA nanotechnology has further accelerated the diversification of synthetic mRNA. Together with advances in synthesis, purification, and delivery technologies, these innovations are transforming mRNA from a transient messenger into a designable molecular system. This review revisits the evolution of mRNA engineering-from natural optimization to creative structural redesign-and outlines emerging concepts that illustrate how synthetic mRNA is expanding the possibilities of gene expression control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.